Showing results (421-430 of 548) with videos related to
Sort By:
Pageof 55
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.Angewandte Chemie (International Ed. in English)|February 26, 2019
An Aqueous Dual-Ion Battery Cathode of Mn3 O4 via Reversible Insertion of NitrateHeng Jiang, Zhixuan Wei, Lu Ma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard, Morton Coleman, Lale Kostakoglu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.Cancer|June 8, 2019
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)Kristie A Blum, Mei-Yin Polley, Sin-Ho Jung, et al.Journal of Endourology|May 6, 2020
Dual-Energy Computed Tomography for Stone Type Assessment: A Pilot Study of Dual-Energy Computed Tomography with Five IndicesVadim Rudenko, Natalia Serova, Lida Kapanadze, et al.Leukemia|March 21, 2003
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002P M Navolanic, C-H Pui, R A Larson, et al.Blood Advances|June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphomaW Richard Burack, Hongli Li, Diana Adlowitz, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.Pageof 55